SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
141.60    -24.20 (-14.60%)
Bid:
140.20
Ask:
144.80
Spread: 4.60 (3.281%)
Market Cap: £241.94m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Directorate Change

26 Jun 2019 07:00

RNS Number : 4151D
McBride PLC
26 June 2019
 

26 June 2019

 

McBride plc

 

Directorate change

 

McBride plc ("McBride" or the "Company") announces the appointment of Jeffrey Nodland as a Non-Executive Director with immediate effect.

 

Jeffrey has extensive experience in consumer chemicals manufacturing businesses including both private label and contract manufacturing activities. He was most recently President and CEO of KIK Custom Products, one of North America's largest independent manufacturers of consumer packaged goods, where between February 2008 and January 2019 he led the turnaround and growth of the business both organically and via acquisition.

 

Previously, Jeffrey held senior positions at speciality chemical businesses including Hexion Speciality Chemicals, Inc., McWhorter Technologies and The Valspar Corporation, with responsibility for activities at a number of speciality chemical plants in western and central Europe, including the UK, Belgium, Italy and Germany.

 

Jeffrey is currently an independent non-executive director of EcoSynthetix, a developer and manufacturer of bio-based polymers for the wood composite and paper industry, which is listed on the Toronto Stock Exchange, and a board member of Augsburg University, Minneapolis. He is a US citizen.

 

Jeffrey will become a member of the Nomination, Remuneration and Audit Committees.

 

John Coleman, Chairman of McBride, said: "We are delighted that Jeff has agreed to join us at McBride. His extensive experience in the household and personal care industry as well as private label and contract manufacturing will bring additional relevant experience to McBride and prove invaluable to the Board in our future discussions."

 

 

McBride has been notified that there are no further details to be disclosed in respect of Jeffrey Nodland pursuant to Rule 9.6.13 of the Listing Rules of the UK Listing Authority

 

 

McBride plc

 

John Coleman, Chairman

0161 203 7570

Rik De Vos, CEO

 

 

 

FTI Consulting

 

Ed Bridges, Nick Hasell

020 3727 1017

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAEAFKSALANEAF
Date   Source Headline
12th Jun 20267:00 amRNSTrading and Acquisition Update
11th Jun 20261:44 pmRNSDirector/PDMR Shareholding
2nd Jun 20267:00 amRNSTransaction in Own Shares
27th May 20267:00 amRNSTransaction in Own Shares
19th May 20267:00 amRNSTransaction in Own Shares
12th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSTransaction in Own Shares
1st May 20267:00 amRNSSecond tranche of share buyback programme
1st May 20267:00 amRNSTransaction in Own Shares
29th Apr 20267:00 amRNSTransaction in Own Shares
28th Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20267:00 amRNSTransaction in Own Shares
16th Apr 20267:00 amRNSTransaction in Own Shares
15th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSProposed Acquisition & Trading Conditions Update
1st Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSDirector Appointment
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20266:28 pmRNSDirectorate change
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:05 amRNSInterim results for 6M ended 31 December 2025

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.